Virtual Reality Training Dose for Arm Recovery After Stroke: Clinical and Blood Biomarker Responses
NCT07919301, Not applicable, Not yet recruiting, Kutahya Health Sciences University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Virtual Reality Training Dose for Arm Recovery After Stroke: Clinical and Blood Biomarker Responses | ClinicalTrials.gov |
| NCT number | NCT07919301 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 72 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Kutahya Health Sciences University | ClinicalTrials.gov |
| Conditions | Stroke, Upper Extremity Paresis | ClinicalTrials.gov |
| Interventions | Neuroforma virtual reality training, Conventional rehabilitation program, Home exercise program | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Fugl-Meyer Assessment for Upper Extremity (FMA-UE) Motor Score From Baseline to Week 12 | Baseline and week 12 (8 weeks after the end of the 4-week intervention) | Upper-limb motor impairment measured with the motor domain of the FMA-UE (33 items scored 0 to 2; total 0 to 66, higher scores indicate better motor function), administered by an assessor blinded to group allocation. Change = week-12 score minus baseline score. | ClinicalTrials.gov |
| Secondary | Change in FMA-UE Motor Score From Baseline to Week 4 | Baseline and week 4 (end of the intervention) | FMA-UE motor domain (0 to 66; higher scores indicate better motor function), blinded assessor. Change = week-4 score minus baseline score. | ClinicalTrials.gov |
| Secondary | Change in Wolf Motor Function Test Functional Ability Scale (WMFT-FAS) Score | Baseline, week 4 and week 12 | Quality of movement rated 0 to 5 on each of the 15 timed WMFT tasks (total 0 to 75; higher scores indicate better upper-limb function), blinded assessor. | ClinicalTrials.gov |
| Secondary | Change in Wolf Motor Function Test Performance Time | Baseline, week 4 and week 12 | Mean time in seconds to complete the 15 timed WMFT tasks (each task capped at 120 seconds); lower values indicate better performance. Blinded assessor. | ClinicalTrials.gov |
| Secondary | Change in Action Research Arm Test (ARAT) Score | Baseline, week 4 and week 12 | 19 items in 4 subtests (grasp, grip, pinch, gross movement), each scored 0 to 3; total 0 to 57, higher scores indicate better upper-limb function. Blinded assessor. | ClinicalTrials.gov |
| Other | Change in Serum Brain-Derived Neurotrophic Factor (BDNF) Concentration (Exploratory) | Baseline, week 4 and week 12 | Fasting venous blood drawn between 08:00 and 10:00; serum stored at -80 °C and measured in batches with a commercial ELISA kit by laboratory staff blinded to group allocation. Exploratory outcome. | ClinicalTrials.gov |
| Other | Change in Serum Irisin Concentration (Exploratory) | Baseline, week 4 and week 12 | Fasting venous blood drawn between 08:00 and 10:00; serum stored at -80 °C and measured in batches with a commercial ELISA kit by laboratory staff blinded to group allocation. Exploratory outcome. | ClinicalTrials.gov |
| Other | Change in Serum S100B Concentration (Exploratory) | Baseline, week 4 and week 12 | Fasting venous blood drawn between 08:00 and 10:00; serum stored at -80 °C and measured in batches with a commercial ELISA kit by laboratory staff blinded to group allocation. Exploratory outcome. | ClinicalTrials.gov |
| Other | Number of Participants With Adverse Events, Including Cybersickness | Baseline to week 12 | Adverse events and cybersickness symptoms recorded daily during the 4-week intervention and at each follow-up visit. | ClinicalTrials.gov |
| Other | Adherence to the Allocated Intervention | Baseline to week 4 | Percentage of scheduled conventional rehabilitation and VR sessions completed. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)